As of 2025-03-15, the EV/EBITDA ratio of Lineage Cell Therapeutics Inc (LCTX) is -4.39. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. LCTX's latest enterprise value is 91.15 mil USD. LCTX's TTM EBITDA according to its financial statements is -20.78 mil USD. Dividing these 2 quantities gives us the above LCTX EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | - | - |
| Forward P/E multiples | - | - |
| Fair Price | - | - |
| Upside | - | - |
| Date | EV/EBITDA |
| 2025-03-11 | -4.53 |
| 2025-03-10 | -4.51 |
| 2025-03-07 | -4.44 |
| 2025-03-06 | -4.49 |
| 2025-03-05 | -4.38 |
| 2025-03-04 | -4.53 |
| 2025-03-03 | -4.28 |
| 2025-02-28 | -4.84 |
| 2025-02-27 | -4.98 |
| 2025-02-26 | -5.55 |
| 2025-02-25 | -5.73 |
| 2025-02-24 | -5.96 |
| 2025-02-21 | -6.10 |
| 2025-02-20 | -6.29 |
| 2025-02-19 | -6.57 |
| 2025-02-18 | -6.64 |
| 2025-02-14 | -6.31 |
| 2025-02-13 | -6.20 |
| 2025-02-12 | -5.71 |
| 2025-02-11 | -5.86 |
| 2025-02-10 | -5.88 |
| 2025-02-07 | -6.03 |
| 2025-02-06 | -6.31 |
| 2025-02-05 | -6.47 |
| 2025-02-04 | -5.92 |
| 2025-02-03 | -6.25 |
| 2025-01-31 | -5.27 |
| 2025-01-30 | -5.55 |
| 2025-01-29 | -5.29 |
| 2025-01-28 | -5.59 |
| 2025-01-27 | -5.43 |
| 2025-01-24 | -5.66 |
| 2025-01-23 | -5.59 |
| 2025-01-22 | -6.09 |
| 2025-01-21 | -5.14 |
| 2025-01-17 | -5.13 |
| 2025-01-16 | -4.95 |
| 2025-01-15 | -5.03 |
| 2025-01-14 | -4.71 |
| 2025-01-13 | -5.25 |
| 2025-01-10 | -5.04 |
| 2025-01-08 | -4.52 |
| 2025-01-07 | -5.07 |
| 2025-01-06 | -4.71 |
| 2025-01-03 | -5.15 |
| 2025-01-02 | -4.33 |
| 2024-12-31 | -4.19 |
| 2024-12-30 | -4.12 |
| 2024-12-27 | -4.13 |
| 2024-12-26 | -4.22 |